Articles

EUROoCS Annual Meeting 2026: What to Expect

The EUROoCS Annual Meeting 2026 promises to be a pivotal event for B2B stakeholders in the pharmaceutical industry. With a focus on critical data and emerging trends, attendees can expect valuable insights.

Roche's Elevidys: A New Hope for DMD Gene Therapy Approval

Roche aims for EMA approval of Elevidys, a gene therapy for DMD, amidst regulatory challenges. This article analyzes the implications for investors and pharma teams.

Ogilvy Health's Insights on AI and Nano Influencers

This article delves into Ogilvy Health's insights on the fast-paced advancements in AI and the growing significance of nano influencers in pharma marketing.

Gilead's $140M Deal with Yuhan: Implications for Pharma

Gilead Sciences has signed a $140M deal with Korean API manufacturer Yuhan. This article explores the implications for pharma teams and investors.

BeOne Launches Campaign with Tim Howard: Implications for Pharma

BeOne has launched the 'One Save Changes Everything' campaign featuring Tim Howard. This article explores the implications for pharmaceutical teams and investors.

Roche's Licensing Deal for Xofluza: Implications and Insights

Roche has signed a significant licensing deal for Xofluza with the Medicines Patent Pool, impacting 129 countries. This article explores the implications for the pharma industry.

Ipsen's Transition Challenges: Insights for Pharma Teams

Ipsen faces challenges in managing the transition of teens to adult care. This article explores the implications for pharmaceutical teams.

Amgen's CFO Transition: Implications for Pharma Investments

Amgen bids farewell to its CFO, attracting a Galderma executive with a substantial bonus. This article delves into the implications for the pharmaceutical industry.

CG Life's Strategic C-Suite Expansion: Collette Douaihy's Appointment

CG Life's recent appointment of Collette Douaihy as Chief Creative Officer marks a significant step in its C-suite buildout, aiming to enhance its creative direction in the pharma sector.

Germany's Bioeconomy Dialogue: Implications for Pharma

This article examines the recent position paper from Germany's BMWE on the European GMO legal framework, focusing on its impact on the pharmaceutical industry.

Pharma Partnering EU 2026: Key Insights and What to Expect

Pharma Partnering EU 2026 is set to be a pivotal event for B2B interactions in the pharmaceutical sector. Here's what you need to know before it starts.

BeOne's New Campaign: A Game Changer for Pharma Marketing

BeOne has launched a new campaign featuring Tim Howard, aiming to reshape pharmaceutical marketing. This article explores the implications for industry stakeholders.

Pharma Partnering EU 2026: Key Insights and Pre-Event Coverage

Pharma Partnering EU 2026 promises to be a pivotal event for B2B stakeholders in the pharmaceutical industry. Get ready for insights on key players, catalysts, and trends.

CG Life's Strategic C-Suite Expansion with New CCO

CG Life has appointed Collette Douaihy as Chief Creative Officer, marking a significant step in its C-suite expansion. This move is expected to enhance its creative strategy in the pharmaceutical marketing landscape.

MaaT Pharma's Regulatory Update on MaaT013 (Xervyteg®)

MaaT Pharma has provided a significant update regarding the marketing authorization application for MaaT013 (Xervyteg®). This article explores the implications for investors and pharma teams.

HLTH Europe 2026: What to Expect from the Upcoming Event

HLTH Europe 2026 is set to be a pivotal event for B2B stakeholders in the healthcare industry. With a focus on innovation and collaboration, this event promises to deliver valuable insights.

IMPHARMA2026: Your Essential Preview of the Upcoming Event

IMPHARMA2026 is set to take place in Copenhagen from June 15-17, 2026. This event promises to be a pivotal moment for B2B stakeholders in the pharma industry.

Amgen's CFO Departure and Galderma's New Executive: What It Means for Pharma

Amgen bids farewell to its CFO, attracting a Galderma executive with a substantial bonus. This article explores the implications for the pharmaceutical industry.

CG Life Strengthens Leadership with New Chief Creative Officer

CG Life has appointed Collette Douaihy as its new Chief Creative Officer, marking a significant step in its C-suite expansion. This move is expected to influence the company's creative direction and market positioning.

Bristol Myers' $1B Manufacturing Plant: Implications for Pharma

Bristol Myers is evaluating a significant investment in a Houston manufacturing plant. This article explores the implications for the pharmaceutical sector.